IFNG and vitiligo: These discoveries provided the rationale to test JAK inhibitors, which block IFNγ signaling, as treatments for vitiligo and eventually led to a successful Phase 2 clinical trial to test topical ruxolitinib as a novel treatment for the disease (137–143).